Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.46 |
| ▸ | DPP4 | P27487 | 6/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22699047 | 0.80 | DPP7 (0.49) | DPP7DPP4DPP8DPP9FAAH | |
| SCHEMBL12947853 | 0.78 | DPP4 (0.51) | DPP7DPP4DPP8DPP9EPHX2 | |
| SCHEMBL16435175 | 0.78 | DPP4 (0.51) | DPP7DPP4DPP8DPP9EPHX2 | |
| SCHEMBL6945729 | 0.78 | DPP7 (0.47) | DPP7DPP4DPP8DPP9FAAH | |
| SCHEMBL9019591 | 0.78 | DPP4 (0.42) | DPP7DPP4DPP8DPP9FAAH | |
| SCHEMBL28071368 | 0.73 | DPP4 (0.82) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL28071366 | 0.73 | DPP4 (0.82) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL1911508 | 0.73 | DPP4 (0.44) | DPP7DPP4DPP8DPP9FAAH | |
| Hydrochloric Acid SCHEMBL28071358 | 0.72 | DPP4 (0.79) | DPP7DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL28071360 | 0.72 | DPP4 (0.79) | DPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | DPP7 44/4885DPP4 36/4885DPP8 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.